Pacira BioSciences, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frank D. Lee
- Full Time Employees
- 829
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2000 Sierra Point Parkway Brisbane CA United States 94005
- IPO Date
- Feb 2, 2011
- CIK
- 0001396814
- Website
- pacira.com
- Similar Companies
- Business
- Pacira BioSciences, Inc. (Nasdaq: PCRX) develops, manufactures, commercializes and sells non-opioid pain management and regenerative health solutions primarily to healthcare practitioners in hospitals and ambulatory surgery centers in the United States. The company offers EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for postsurgical pain management via infiltration, fascial plane block, interscalene brachial plexus nerve block, adductor canal nerve block and sciatic nerve block in the popliteal fossa; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an intra-articular injection for osteoarthritis knee pain management; iovera°, a handheld cryoanalgesia device that delivers controlled cold doses to targeted nerves for drug-free pain relief; and advances PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis and related musculoskeletal conditions utilizing a high-capacity adenovirus vector platform. Founded in 2006 and headquartered in Tampa, Florida, with additional facilities in Brisbane, California; Parsippany, New Jersey; San Diego, California; and international sites including Swindon, UK and Hamburg, Germany, Pacira operates as the holding company for Pacira Pharmaceuticals, Inc. and maintains a development and supply agreement with Aratana Therapeutics for NOCITA, a bupivacaine liposome injectable suspension for veterinary use. In February 2025, Pacira acquired the remaining 81% equity interest in GQ Bio Therapeutics GmbH for approximately $32 million net, building on prior investments and a manufacturing partnership to fully integrate GQ Bio's high-capacity adenovirus gene therapy platform, eliminate up to $64 million in future milestones, and accelerate innovative musculoskeletal therapies including PCRX-201, which showed sustained pain relief through two years in a Phase 1 study reported in November 2024; the company also announced new five-year objectives in October 2025 targeting over three million patients treated annually, double-digit product revenue growth, gross margin expansion and five novel pipeline programs with partnerships.
Company News
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Viatris Reports Third-Quarter 2026 Financial Results
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
2 Stocks Drawing Bearish Options Activity Today
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Viatris to Buy Pacira BioSciences for $1.65 Billion
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders